Use our marquee links to make BioCentury This Week part of your home page! Our player style marquee links below make it very easy to do.
Your Webmaster can follow these easy steps:
- Select the program from the list below to which you want to link.
- Copy the html code in the box for that segment.
- Paste the copied html code into your home page.
If you want to link to multiple segments, select the first of your choices as the marquee link. The segments that follow will play automatically after your selection.
Questions: jfitzgerald@biocentury.com
That's it! You now have a marquee link like the one above.
NOTICE:
BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content on "BioCentury This Week," and except for limited use of these links to the
BioCenturytv.com website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury This Week content to any unauthorized third party websites such as YouTube. Other
BioCenturytv.com content and all trademarks are the property of BioCentury or WUSA-TV or other third parties.
 |
BioCentury 04.10.11 - [1] Makena Redux
Following up the April 3 broadcast, Co-Hosts Steve Usdin and Eric Pierce warn FDA is in "uncharted waters" after announcing compounding pharmacies can still sell versions of KV Pharma's Makena pregnancy drug.
COPY THIS CODE:
|
 |
|
BioCentury 04.10.11 - [2] Taking on FDA
In a "Point of View" interview, Frank Burroughs, President and Founder of Abigail Alliance, describes why he accuses FDA of blocking expanded use access for desperately ill patients.
COPY THIS CODE:
|
|
|
BioCentury 04.10.11 - [3] The Fight
Burroughs argues that Phase I trial data are a valid basis for making unapproved cancer drugs available for compassionate use by patients fighting for their lives.
COPY THIS CODE:
|
|
|
BioCentury 04.10.11 - [4] Interference
Burroughs notes that no cancer drug has being pulled from the market in the past decade for safety reasons, and says FDA is failing to adopt modern tools to advance provisional drugs.
COPY THIS CODE:
|
|
